Latest News and Press Releases
Want to stay updated on the latest news?
-
- Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO - - Preclinical data for two novel next-generation...
-
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment...
-
- SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma - - Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated...
-
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the...
-
- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells - - Data suggests...
-
- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS - - The Company will host its first virtual medical symposium at CTOS - ...
-
- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - - Majority of patients...
-
- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - ...
-
- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - - HiT works as well, or better than, a TRuC...
-
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical...